W. Eiermann
- Cancer Research top 0.02%
- Breast Cancer Treatment Studies 96
- Oncology top 0.02%
- HER2/EGFR in Cancer Research 63
- Cancer Treatment and Pharmacology 58
- PARP inhibition in cancer therapy 17
- Radiology, Nuclear Medicine and Imaging top 0.05%
- Pathology and Forensic Medicine top 0.2%
- Breast Lesions and Carcinomas 21
- Pulmonary and Respiratory Medicine top 0.2%
- Advanced Breast Cancer Therapies 33
-
- Estrogen and related hormone effects 33
- BRCA gene mutations in cancer 20
W. Eiermann
214 papers receiving 23.1k citations
Hit Papers
Peers
Comparison fields: 5 of 147
- Cancer Research 10.0k
- Oncology 16.4k
- Radiology, Nuclear Medicine and Imaging 5.8k
- Pathology and Forensic Medicine 3.0k
- Pulmonary and Respiratory Medicine 4.6k
Countries citing papers authored by W. Eiermann
This map shows the geographic impact of W. Eiermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Eiermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Eiermann more than expected).
Fields of papers citing papers by W. Eiermann
This network shows the impact of papers produced by W. Eiermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Eiermann. The network helps show where W. Eiermann may publish in the future.
Co-authorship network
The 25 scholars most cited alongside W. Eiermann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialbreakdown → | 2020 | 252 |
| 2 | Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutationbreakdown → | 2018 | 1401 |
| 3 | 2018 | 40 | |
| 4 | 2018 | 25 | |
| 5 | 2017 | 17 | |
| 6 | 2015 | 57 | |
| 7 | PTK7 expression in triple-negative breast cancer. | 2013 | 32 |
| 8 | 2013 | 265 | |
| 9 | 2013 | 19 | |
| 10 | 2013 | 172 | |
| 11 | 2012 | 28 | |
| 12 | 2012 | 20 | |
| 13 | 2011 | 13 | |
| 14 | Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. | 2003 | 41 |
| 15 | 2001 | 1 | |
| 16 | 1996 | 207 | |
| 17 | 1989 | 6 | |
| 18 | 1989 | 0 | |
| 19 | [Contrast enhancement of the nipple in nuclear magnetic resonance tomography of the breast with Gd-DTPA]. | 1987 | 2 |
| 20 | [Correlation between ectopic production of beta1-glycoprotein and human placental lactogen and prognosis of breast cancer]. | 1979 | 1 |
About W. Eiermann
W. Eiermann is a scholar working on Cancer Research, Oncology, Genetics, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging, having authored 224 papers that have together received 23.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (96 papers), HER2/EGFR in Cancer Research (63 papers), Cancer Treatment and Pharmacology (58 papers), Advanced Breast Cancer Therapies (33 papers), Estrogen and related hormone effects (33 papers), Breast Lesions and Carcinomas (21 papers), BRCA gene mutations in cancer (20 papers) and PARP inhibition in cancer therapy (17 papers). The work is most often cited by research in Cancer Research (10.0k citations), Oncology (16.4k citations), Radiology, Nuclear Medicine and Imaging (5.8k citations), Pathology and Forensic Medicine (3.0k citations) and Pulmonary and Respiratory Medicine (4.6k citations). W. Eiermann has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include José Baselga, Janet Wolter, Dennis J. Slamon, Mark D. Pegram, Steven Shak, Virginia Paton, Larry Norton, Alex Bajamonde, Thomas Fleming and Brian Leyland‐Jones. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, European Journal of Cancer and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.